Posted by Michael Wonder on 06 Aug 2016
CADTH calls for patient input on a submission from Cipher Pharmaceuticals for Actikerall (5-fluorouracil with salicylic acid)
5 August 2016 - CADTH is calling for patient input on a pending submission from Cipher Pharmaceuticals for Actikerall.
This will be Cipher Pharmaceuticals' first submission to CADTH.
Actikerall was approved by Health Canada last year for topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients.
The submission is due on 31 August 2016.
